STRIDER NZAus

Newsletter 27, June 2016

We have recruited 70% of our STRIDER NZAus target!!

New recruits for June: one participant each enrolled at **KEMH**, Perth, Royal Women's, Melbourne, Mater Mother's, Brisbane, Royal Hospital for Women, Sydney and Auckland City Hospital, congratulations to all!

Recruited to date 85 / 122

With 6 months of the year remaining we are on track to meeting our goal of completing recruitment in 2016! We will achieve this if every site contributes ONE participant every two months. Key messages from our discussion at the collaborators meeting and when speaking to individual sites have highlighted that the most challenging aspect is getting the referrals. While we won't identify all women with early onset IUGR antenatally we would love to see every potentially eligible woman who is diagnosed with IUGR in your hospital's catchment area offered the trial.

- The STRIDER trial is generally well received by those women it is offered to. After the initial approach anywhere from 50 – 80% of women will be confirmed as eligible and choose to take part.
- Introducing the trial at the end of your counselling and then having one of the STRIDER team follow up soon after gives women time to consider the trial in what can be an overwhelming time and demonstrates that the trial is well supported by the department and referring clinicians.
- Having an MFM fellow actively involved in the trial can improve recruitment rates and moderate the workload of the initial protocol assessments.
- Feedback from women who have complete the trial has been positive, most felt reassured by the level of surveillance and would recommend taking part.

Update on the STRIDER IPD Collaborators meeting

Katie attended this meeting in London in April. It was a great opportunity to get an update on the other 4 STRIDER trials - UK completing in August, Netherlands underway, Ireland & Canada recruiting by the end of 2016. It seems very likely that UK & NZAus will be the first into the trial sequential analysis. We also took time to plan longer term follow-up, an umbrella DSMB and our approach to meta-analysis and IPD data analysis. The USA MFM Network are considering joining the Collaboration with a 6th STRIDER trial.



Larry Li, Tang Le, Chirag Kariya, Phil Baker, Katie Groom, Laura Magee, Peter von Dadelszen, Aris Papageorghiou, Christian Gluud (Louise Kenny)

| Women Recruited |
|--------------------|
| 19 |
| 19 |
| 12 |
| 9 |
| 8 |
| 7 |
| 5 |
| 3 |
| 2 |
| 1 |
| 0 |
| |

CONTACT

100 10 Actual 85 80 40 20

Dr Katie Groom, Lead Investigator Laura MacKay, Clinical Trial Manager Mariska ter Bals, Clinical Trial Manager k.groom@auckland.ac.nz laura.mackay@auckland.ac.nz +64 22 4311 988 m.terbals@auckland.ac.nz

+64 21 245 9622

+64 22 4311 988